ACET on Nasdaq
Adicet Bio, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $99.1M | $99.3M |
| General and administrative | $23.0M | $28.3M |
| Total operating expenses | $122.1M | $127.6M |
| Loss from operations | -$122.1M | -$127.6M |
| Interest income | $5.8M | $10.7M |
| Interest expense | -$36.0K | -$4.0K |
| Other expense, net | -$430.0K | -$217.0K |
| Loss before income tax provision | -$116.8M | -$117.1M |
| Income tax provision | $0 | $0 |
| Net loss | -$116.8M | -$117.1M |
| Net loss per share, basic | -$16.95 | -$21.33 |
| Net loss per share, diluted | -$16.95 | -$21.33 |
| Weighted-average common shares used in computing net loss per share, basic | 6.9M shares | 5.5M shares |
| Weighted-average common shares used in computing net loss per share, diluted | 6.9M shares | 5.5M shares |
| Unrealized gain on treasury securities, net of tax | $86.0K | $16.0K |
| Total other comprehensive income | $86.0K | $16.0K |
| Comprehensive loss | -$116.7M | -$117.1M |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $38.9M | $56.5M | |
| Short-term investments in treasury securities | $119.6M | $119.8M | |
| Prepaid expenses and other current assets | $2.4M | $3.8M | |
| Total current assets | $160.9M | $180.1M | |
| Restricted cash | $2.9M | $2.9M | |
| Property and equipment, net | $16.5M | $22.5M | |
| Operating lease right-of-use asset | $10.9M | $14.2M | |
| Finance lease right-of-use asset | $1.0M | $0 | |
| Other non-current assets | $76.0K | $428.0K | |
| Total assets | $192.4M | $220.2M | |
| Accounts payable | $4.7M | $4.8M | |
| Accrued and other current liabilities | $13.6M | $11.4M | |
| Operating lease liability | $2.8M | $3.1M | |
| Finance lease liability | $349.0K | $0 | |
| Total current liabilities | $21.5M | $19.4M | |
| Operating lease liability, net of current portion | $10.9M | $14.1M | |
| Finance lease liability, net of current portion | $642.0K | $0 | |
| Other non-current liabilities | $62.0K | $116.0K | |
| Total liabilities | $33.1M | $33.6M | |
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; none issued and outstanding as of December 30, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Common stock, $0.0001 par value, 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 9,586,770 and 5,160,545 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $10.0K | $5.0K | |
| Additional paid-in capital | $773.8M | $684.5M | |
| Accumulated deficit | -$614.7M | -$497.9M | |
| Accumulated other comprehensive income | $102.0K | $16.0K | |
| Total stockholders' equity | $159.2M | $186.6M | |
| Total liabilities and stockholders' equity | $192.4M | $220.2M | |
| Common stock price per share | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares issued | 9.6M shares | 5.2M shares | |
| Common stock, shares outstanding | 9.6M shares | 5.2M shares | |
| Preferred Stock, par value | $0.00 | $0.00 | |
| Preferred stock shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock shares issued | 0 shares | 0 shares | |
| Preferred stock shares outstanding | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$116.8M | -$117.1M |
| Depreciation and amortization expense | $6.4M | $6.5M |
| Noncash lease expense | $3.4M | $3.2M |
| Stock-based compensation expense | $14.3M | $22.2M |
| Loss on disposal of property and equipment | $103.0K | $0 |
| Net amortization of premiums and accretion discounts on investments | -$4.1M | -$1.7M |
| Amortization of deferred transaction costs | $43.0K | $39.0K |
| Prepaid expenses and other current assets | $1.7M | -$1.3M |
| Other non-current assets | $308.0K | $353.0K |
| Accounts payable | $1.0M | $1.1M |
| Operating lease liability | -$3.4M | -$3.7M |
| Accrued and other current and non-current liabilities | $1.9M | -$2.0M |
| Net cash used in operating activities | -$95.2M | -$92.4M |
| Purchases of short-term treasury securities | -$140.9M | -$129.1M |
| Maturities of short term treasury securities | $145.0M | $11.0M |
| Purchase of property and equipment | -$1.7M | -$1.1M |
| Net cash provided by (used in) investing activities | $2.4M | -$119.2M |
| Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs | $0 | $19.3M |
| Proceeds from issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance costs | $75.2M | $91.7M |
| Proceeds from exercise of stock options | $1.0K | $195.0K |
| Proceeds from Employee Stock Purchase Plan | $326.0K | $335.0K |
| Taxes withheld and paid related to net share settlement of equity awards | -$104.0K | -$141.0K |
| Principal payments on finance leases | -$150.0K | |
| Net cash provided by financing activities | $75.2M | $111.3M |
| Net change in cash, cash equivalents and restricted cash | -$17.6M | -$100.3M |
| Purchases of property and equipment included in accounts payable and accrued expenses | $209.0K | $1.5M |
| Right-of-use asset acquired under finance leases | $1.1M | |
| Offering costs in accounts payable and accrued expenses | $344.0K |
Former names
- resTORbio, Inc.Oct 27, 2017 to Aug 21, 20202
Recent filings
- Sep 28, 20268-K
- Sep 8, 20268-K
- Sep 1, 20268-K
- Aug 14, 2026SCHEDULE 13G/A
- Aug 7, 20264
- Aug 5, 20268-K
- Aug 5, 202610-Q
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10